伏隔核脑深部电刺激治疗难治性阿片类药物使用障碍的安全性与可行性临床试验
前瞻性开放标签单臂研究纳入4例长期难治性阿片类药物使用障碍(OUD)男性患者,行伏隔核/腹侧内囊(NAc/VC)脑深部电刺激(DBS),主要终点安全性,全部耐受手术且无严重不良事件(AEs)及装置或刺激相关AEs;2例持续戒断分别超过1150天和520天,另1例复发频率和严重程度降低,1例因不依从方案取出装置。
要点
- 4例难治性OUD患者行NAc/VC DBS,全部耐受手术,无严重AEs及装置或刺激相关AEs。
- 2例持续戒断分别超过1150天和520天,渴求、焦虑、抑郁显著降低。
- 1例DBS后复发但频率和严重程度降低;1例因不依从治疗要求和研究方案取出DBS系统。
核心结论
- NAc/VC DBS安全、可行,可能减少难治性OUD患者的物质使用、渴求和情绪症状。
- 正在启动更大队列的随机假刺激对照试验。
研究设计与样本
- 前瞻性、开放标签、单臂研究,纳入长期难治性OUD(伴其他共病SUD)并接受NAc/VC DBS的参与者,主要终点为安全性,次要/探索性结局包括随访期间阿片及其他物质使用、物质渴求和情绪症状及18FDG-PET神经影像。
主要发现
- 4例男性参与者全部耐受DBS手术,无严重AEs,无装置或刺激相关AEs。
- 2例分别持续完全戒断物质超过1150天和超过520天,DBS后物质渴求、焦虑和抑郁显著降低。
- 1例DBS后出现药物使用复发,频率和严重程度降低。
- 1例因不依从治疗要求和研究方案而取出DBS系统。
- 18FDG-PET神经影像显示仅持续戒断的参与者额区葡萄糖代谢增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There were more than 107,000 drug overdose deaths in the US in 2021, the most ever recorded. Despite advances in behavioral and pharmacological treatments, over 50% of those receiving treatment for opioid use disorder (OUD) experience drug use recurrence (relapse). Given the prevalence of OUD and other substance use disorders (SUDs), the high rate of drug use recurrence, and the number of drug overdose deaths, novel treatment strategies are desperately needed. The objective of this study was to evaluate the safety and feasibility of deep brain stimulation (DBS) targeting the nucleus accumbens (NAc)/ventral capsule (VC) and potential impact on outcomes in individuals with treatment-refractory OUD. METHODS: A prospective, open-label, single-arm study was conducted among participants with longstanding treatment-refractory OUD (along with other co-occurring SUDs) who underwent DBS in the NAc/VC. The primary study endpoint was safety; secondary/exploratory outcomes included opioid and other substance use, substance craving, and emotional symptoms throughout follow-up and 18FDG-PET neuroimaging. RESULTS: Four male participants were enrolled and all tolerated DBS surgery well with no serious adverse events (AEs) and no device- or stimulation-related AEs. Two participants sustained complete substance abstinence for > 1150 and > 520 days, respectively, with significant post-DBS reductions in substance craving, anxiety, and depression. One participant experienced post-DBS drug use recurrences with reduced frequency and severity. The DBS system was explanted in one participant due to noncompliance with treatment requirements and the study protocol. 18FDG-PET neuroimaging revealed increased glucose metabolism in the frontal regions for the participants with sustained abstinence only. CONCLUSIONS: DBS of the NAc/VC was safe, feasible, and can potentially reduce substance use, craving, and emotional symptoms in those with treatment-refractory OUD. A randomized, sham-controlled trial in a larger cohort of patients is being initiated.
引用
- Rezai AR, Mahoney JJ, Ranjan M, et al. Safety and feasibility clinical trial of nucleus accumbens deep brain stimulation for treatment-refractory opioid use disorder. J Neurosurg. 2023. PMID: 37329519. doi:10.3171/2023.4.JNS23114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。